Core Insights - Chicago Partners Investment Group LLC increased its holdings in Illumina, Inc. by 90.5% in Q3, owning 9,908 shares valued at $969,000 after acquiring an additional 4,708 shares [2] - Other institutional investors also increased their stakes, with Empowered Funds LLC raising its position by 113.7% and acquiring 9,284 shares worth $737,000 [3] - Illumina reported Q3 earnings of $1.34 per share, exceeding estimates of $1.16, with revenue of $1.08 billion, slightly above the consensus of $1.07 billion [5] Institutional Holdings - 89.42% of Illumina's stock is owned by institutional investors and hedge funds [3] - Notable increases in holdings include GAMMA Investing LLC, which boosted its stake by 199.5% in Q2, now owning 2,465 shares valued at $235,000 [3] Stock Performance - Illumina's stock opened at $150.28, with a market cap of $22.96 billion, a PE ratio of 33.70, and a 52-week range of $68.70 to $155.53 [4] - The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12, and a current ratio of 1.43 [4] Analyst Ratings - Barclays raised its price target for Illumina from $100.00 to $110.00, maintaining an "underweight" rating [6] - Six analysts rated the stock as a Buy, twelve as Hold, and two as Sell, with an average target price of $124.47 [6] Insider Transactions - Director Scott Gottlieb acquired 500 shares at an average cost of $122.13, increasing his ownership by 4.16% [7] - Insider Scott M. Davies sold 323 shares at an average price of $136.09, resulting in a 1.77% decrease in his ownership [8] Company Overview - Illumina, Inc. is a global life sciences company specializing in genetic analysis systems, headquartered in San Diego, California [9] - The company offers next-generation sequencing platforms, microarrays, and related technologies for various research applications [10]